ARQT
Arcutis Biotherapeutics Inc
24.20$
+1.0%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +308.4% | -6.1% | +86.6% | +634.3% | -64.5% | +266.5% | -37.7% | +45.0% | +59.4% | -7.7% | +23.8% | +21.7% | +30.5% | -18.6% | +23.2% | – | |
| – | – | – | – | – | – | – | – | +8.3% | -12.3% | – | – | +7.2% | +2.2% | +5.5% | +9.9% | +8.5% | +2.2% | +15.0% | +80.3% | +61.4% | -0.9% | +52.3% | +90.0% | +45.0% | +6.4% | +58.9% | +25.5% | +27.9% | -15.2% | +15.9% | +34.6% | -16.3% | +11.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +443.0% | -19.3% | +120.9% | +736.6% | -69.5% | +310.6% | -40.9% | +43.3% | +64.2% | -11.5% | +29.8% | +22.3% | +30.1% | -18.8% | +24.4% | – | |
| – | +0.0% | +156.9% | -24.5% | +16.0% | +16.3% | +71.2% | -12.9% | +134.1% | +19.2% | +9.1% | -16.4% | -21.0% | +42.2% | +32.0% | +29.4% | -22.7% | -5.9% | +82.5% | -51.4% | +4.3% | -28.6% | +4.0% | -9.4% | -2.7% | -16.6% | +1.1% | -25.7% | +21.2% | +10.9% | +0.8% | +4.3% | +49.8% | -33.5% | – | |
| – | +0.0% | +113.6% | -1.3% | +23.6% | +76.8% | +73.7% | -2.7% | +55.1% | +61.9% | -1.0% | +20.3% | +116.1% | -21.7% | +45.6% | +13.7% | +17.5% | +25.5% | +28.4% | +39.9% | -88.3% | +693.6% | +3.6% | +186.7% | -59.8% | +6.2% | +1.1% | -2.1% | +11.1% | +8.1% | -9.8% | +26.6% | -6.2% | +10.9% | – | |
| – | +0.0% | +154.2% | -22.1% | +16.8% | +22.8% | +71.6% | -11.7% | +121.0% | +24.4% | +7.7% | -11.1% | +5.4% | +16.7% | +35.8% | +24.9% | -12.2% | +5.1% | +60.4% | -32.6% | +10.4% | -9.1% | +3.7% | -1.9% | +7.6% | -0.6% | +1.1% | -8.0% | +13.1% | +8.7% | -7.5% | +21.2% | +5.3% | -2.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +115.7% | -149.4% | – | – | |
| – | – | – | – | – | +0.0% | +0.0% | – | – | – | – | – | – | – | – | – | – | +8.8% | +145.0% | +41.2% | +1.8% | +4.4% | +2.9% | +2.7% | -3.6% | +0.1% | -11.1% | -16.6% | -46.3% | +1.6% | +1.4% | -2.3% | +45.6% | -22.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +138.5% | -162.7% | – | – | |
| – | +0.0% | -63.0% | -29,865.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | -6.9% | +87.5% | +21.4% | -110.1% | – | -70.0% | -99.2% | +1,196.0% | +0.0% | – | – | -13.6% | +22.6% | -76.6% | +487.5% | -80.2% | +46.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +134.8% | -164.9% | – | – | |
| – | +0.0% | -63.0% | -29,865.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +98.9% | -128.3% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.